The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: Preliminary findings

Neuropsychopharmacology

Volumn 38, Issue 10, 2013, Pages 1921-1928

  Musselman, Dominique ^a   Royster, Erica B ^b   Wang, Ming ^c   Long, Qi ^c   Trimble, Lisa M ^b   Mann, Tara K ^b   Graciaa, Daniel S ^b   McNutt, Marcia D ^b   Auyeung, N S Freda ^b   Oliver, Lindsay ^b   Lawson, David H ^d   Miller, Andrew H ^b,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

adrenocorticotropin (ACTH); depression; escitalopram; interleukin 2; interleukin 6; melanoma

Indexed keywords

CORTICOTROPIN; ESCITALOPRAM; HYDROCORTISONE; INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; ARTICLE; BEHAVIOR CHANGE; BRAIN METASTASIS; CANCER STAGING; CLINICAL ARTICLE; COLON INTUSSUSCEPTION; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HAMILTON SCALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; MAJOR DEPRESSION; MALE; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE SYSTEM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT REFUSAL;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; CITALOPRAM; DEPRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCORTISONE; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MEDICATION ADHERENCE; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84882453531     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.85     Document Type: Article

References (45)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th edn. American Psychiatric Association: Washington, DC, USA.
2. Anisman H, Merali Z (1999). Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 461: 199-233.
3. Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R et al (1983). Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 47: 123-133.
4. Butler LD, Mohler KM, Layman NK, Cain RL, Riedl PE, Puckett LD et al (1989). Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic intervention. Immunopharmacol Immunotoxicol 11: 445-487.
5. Capuron L, Ravaud A, Dantzer R (2000). Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18: 2143-2151.
6. Capuron L, Ravaud A, Dantzer R (2001). Timing and specificity of the cognitive changes induced by interleukin-2 and interferonalpha treatments in cancer patients. Psychom Med 63: 376-386.
7. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH (2003). An exaggerated HPA axis response to the initial injection of interferon-alpha is associated with the development of depression during interferon-alpha therapy. Am J Psychiatry 160: 1342-1345.
8. Carlin JM, Borden EC, Sondel PM, Byrne GI (1987). Biologicresponse- modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 139: 2414-2418.
9. Chambrier C, Mercatello A, Tognet E, Cottet-Emard JM, Cohen R, Blay JY et al (1990). Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients. J Biol Response Modif 9: 251-255.
10. Denicoff KD, Ribinow DR, Papa MZ, Simpson C, Seippp CA, Lotze MT et al (1987). The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 69: 402-410.
11. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM et al (2007). Effects of interferon-alpha on rhesus monkeys: a non-human primate model of cytokine-induced depression. Biol Psychiatry 62: 1324-1333.
12. First MB, Spitzer RL, Gibbon M, Williams JBW (1998). Structured Clinical Interview for DSM-IV Axis I Disorders SCID I: Clinician Version 2.0. Rev. Biometrics Research Department, New York State Psychiatric Institute: New York, NY, USA.
13. Folstein MF, Folstein SE, McHugh A (1975). "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 12: 189-198.
14. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ (2012). Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 69: 572-579.
15. Goleva E, Kisich KO, Leung DY (2002). A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance. J Immunol 169: 5934-5940.
16. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
17. Hanisch UK, Rowe W, Sharma S, Meaney MJ, Quirion R (1994). Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2.
18. Endocrinology 135: 2465-2472.
19. Hillhouse EW (1994). Interleukin-2 stimulates the secretion of arginine vasopressin but not corticotropin-releasing hormone from rat hypothalamic cells in vitro. Brain Res 650: 323-325.
20. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM (2002). p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109: 649-657.
21. Jiang C, Lu C (1998). Interleukin-2 and its effects in the central nervous system. Biol Signals Recept 7: 148-156.
22. Karanth S, McCann SM (1991). Anterior pituitary hormone control by interleukin-2. Proc Natl Acad Sci USA 88: 2961-2965.
23. Katahira M, Iwasaki Y, Aoki Y, Oiso Y, Saito H (1998). Cytokine regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. Endocrinology 129: 2414-2422.
24. Lacosta S, Merali Z, Anisman H (2000). Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation 8: 83-90.
25. Montgomery S, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
26. Musselman DL, Lawson DH, Gumnick JF, Penna S, Goodkin R, Greiner K et al (2001). Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferonalpha therapy. N Engl J Med 344: 961-966.
27. National Institute for Clinical Excellence (2004). Depression: Management of Depression in Primary and Secondary Care. National Institute for Clinical Excellence: London, England.
28. Nicolson SE, Miller AH, Lawson D, Musselman DL (2006). Neuropsychiatric effects of IL-2: mechanisms and treatment implications. Depression: Mind and Body 2: 120-129.
29. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to the pathophysiology and treatment. Biol Psychiatry 49: 391-404.
30. Perraudin V, Delarue C, Lefebvre H, Contesse V, Kuhn JM, Vaudry H (1993). Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J Clin Endocrinol Metab 76: 1522-1528.
31. Raab C, Weidmann E, Schmidt A, Bregmann L, Badenhoop K, Usadel KH et al (1999). The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitaryadrenal axis. Clin Endocrinol (Oxf) 50: 37-44.
32. Raber J, Bloom FE (1994). IL-2 induces vasopressin release from the hypothalamus and the amygdala: role of nitric oxidemediated signaling. J Neurosci 14: 6187-6195.
33. Raber J, Koob GF, Bloom FE (1995). Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling: comparison with the hypothalamic response. J Pharmacol Exp Ther 272: 815-824.
34. Raison CL, Dantzer D, Kelley KW, Lawson MC, Woolwine BJ, Vogt G et al (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15: 393-403.
35. Raison CL, Miller AH (2003a). When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 160: 1554-1565.
36. Raison CL, Miller AH (2003b). Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 54: 283-294.
37. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA et al (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474-485.
38. Saraya KA, Balkwill FR (1993). Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression. Br J Cancer 67: 514-521.
39. Schutte NS, Malouff JM (1995). Sourcebook of Adult Assessment Strategies. Plenum Press: New York, NY, USA.
40. Shao J, Zhang B (2003). Last observation carry-forward and last observation analysis. Stat Med 22: 2429-2441.
41. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH (1992). Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10: 1119-1123.
42. Song P, Lie-Cheng W, Wang GD, Zhou Z, Zhao ZQ (2002). Interleukin-2 regulates membrane potentials and calcium channels via mu opioid receptors in rat dorsal root ganglion neurons. Neuropharmacology 43: 1324-1329.
43. Spina MP, Santi G, Poggiato M, Bacchioni G, Sacca G, Cerri A et al (1994). In vitro effects of IL-2 on human hypophyseal adenoma. Minerva Endocrinol 19: 163-168.
44. Spinazzé S, Viviani S, Bidoli P, Rovelli F, Palmer P, Franks CR et al (1991). Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and betaendorphin in advanced small cell lung cancer patients. Tumori 77: 496-499.
45. Witzke O, Winterhagen T, Kribben A, Philipp T, Mann K, Reinhardt W (2003). Interleukin-2 given to asymptomatic HIV-infected individuals leads to an exaggerated response of the pituitary gland to the action of CRH. Clin Endocrinol 59: 104-109..